INCY news

Incyte reported total revenue of $1.56 billion for the third quarter, up 14% driven by strong net sales growth. This underscores the company's expanding commercial footprint beyond its core ruxolitinib franchise.

Incyte completed the acquisition of Vega Therapeutics for $1.25 billion upfront, adding Phase 3 VWD asset VGA039. This deal significantly strengthens the company's hematology pipeline with a potential first-in-class therapy.

Incyte agreed to acquire Vega Therapeutics, a Star Therapeutics subsidiary, to add VGA039, a Phase 3 bleeding disorder treatment candidate to its hematology portfolio. The deal expands Incyte's offerings in a core therapeutic area with potential commercial upside from a first-in-class subcutaneous t…